Please login to the form below

Not currently logged in
Email:
Password:

Bump in the road slows momentum for BMS' Opdivo

FDAturns down the cancer treatment for a form of melanoma

Bristol-Myers Squibb (BMS)After sailing through a string of earlier FDA approvals, Bristol-Myers Squibb's Opdivo has been turned down by the agency for a particular form of melanoma.

Last week, the US regulator gave the thumbs-up to Opdivo (nivolumab) as a first-line, single-agent treatment for patients with 'wild-type' BRAF melanoma, a group that does not generally respond to treatment with BRAF inhibitors such as Roche's Zelboraf (vemurafenib).

It has previously also approved the combination of Opdivo and BMS' CTLA4 inhibitor Yervoy (ipilimumab) as a therapy for BRAF wild-type melanoma patients. 

Now, the FDA says it needs additional information before it can approve Opdivo as a single-agent therapy in patients whose tumours test positive for BRAF V600 mutations. About 50% of all melanomas harbour BRAF mutations, and 90% of these are BRAF V600E. 

In a statement, BMS said it is trying "to determine whether additional data, currently under review, adequately addresses these comments". 

The company has already submitted data from its CheckMate-067 trial evaluating Opdivo as a single agent and in combination and Yervoy in patients with previously-untreated advanced melanoma, which included patients with both wild type and BRAF V600-positive tumours.

Data from this study has already been submitted to the FDA as part of a dossier seeking to expand the label for Opdivo and the Opdivo/Yervoy combination in advanced melanoma, with an FDA action date of January 23, 2016.

The FDA response is the first setback for the product, which has amassed several FDA approvals in recent months that have propelled sales to $467m in the first nine months of the year, the bulk of that ($300m-plus) in the third quarter.

Any brake applied to the drug's momentum in melanoma is likely to be overcome by Opdivo's recent approval in renal cell carcinoma, an indication estimated to be worth at least $1bn in sales in its own right.

Article by
Phil Taylor

30th November 2015

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics